Literature DB >> 1695111

Effects of recombinant human G-CSF, GM-CSF, IL-3, and IL-1 alpha on the growth of purified human peripheral blood progenitors.

Y Takaue1, Y Kawano, C L Reading, T Watanabe, T Abe, T Ninomiya, E Shimizu, T Ogura, Y Kuroda, A Yokobayashi.   

Abstract

The effects of recombinant products of granulocyte colony-stimulating factors (G-CSF), granulocyte/macrophage CSF (GM-CSF), human interleukin-3 (IL-3), and interleukin-1 (IL-1) were studied using purified target cell populations from patients undergoing peripheral blood stem cell transplantation after myeloablative therapy. Cells were subjected to combined purification procedures including negative selection with a panel of monoclonal antibodies (CD2, 3, 5, 10, and 20). The purified cells were enriched for HLA-DR+ (51% to 71%) and My-10+ (CD34; 37% to 54%) and had a plating efficiency of up to 20%. In the liquid-suspension limiting dilution clonal assay (LDA), purified progenitors responded directly to IL-3 by proliferation with single-hit kinetics. The ability of GM-CSF to support progenitor growth was inferior to that of IL-3, and the cells were virtually unresponsive when cultured with G-CSF, supporting the notion that these blood-derived progenitors belong to a primitive population of hematopoietic progenitor cells. The results obtained in simultaneous methycellulose cultures (MC) showed the same trend and provided additional information on the ability of GM-CSF and IL-3 to support erythroid progenitor growth. The combination of IL-3 plus G-CSF, but not IL-3 plus GM-CSF, resulted in a synergistic increase in colony number. IL-1 alpha increased both the size and number of colonies when added to IL-3 or G-CSF. Study of this enriched progenitor cell population in MC and LDA represents an excellent model for the investigation of myeloid and erythroid differentiation and for evaluating the influence of various cytokines on human hematopoiesis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1695111

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  9 in total

1.  Combination of recombinant cytokines fails to produce ex vivo expansion of human blood hematopoietic progenitor cells.

Authors:  Y Takaue; T Abe; Y Kawano; A Hirao; A Yokobayashi; Y Okamoto; S Saito; T Shimizu; J Sato; T Watanabe
Journal:  Ann Hematol       Date:  1992-05       Impact factor: 3.673

2.  Analysis of CD34-positive hemopoietic progenitor cells from normal human adult peripheral blood: flow-cytometrical studies and in-vitro colony (CFU-GM, BFU-E) assays.

Authors:  S Serke; S Säuberlich; Y Abe; D Huhn
Journal:  Ann Hematol       Date:  1991 Feb-Mar       Impact factor: 3.673

3.  The growth capacity of hematopoietic progenitor cells in severe neutropenia induced by famotidine.

Authors:  T Liersch; J H Beyer; G Krieger; K Vehmeyer
Journal:  Ann Hematol       Date:  1992-05       Impact factor: 3.673

4.  IL-2, IL-3, and IFN-gamma differently affect in vivo frequencies of circulating precursors of cytotoxic T lymphocytes (CTL-P).

Authors:  F Hladik; K Kolbe; E U Irschick; M J Aman; G Gerken; L Färber; E Liehl; C Peschel; W E Aulitzky; C Huber
Journal:  Ann Hematol       Date:  1993-08       Impact factor: 3.673

Review 5.  The role of GM-CSF in infection.

Authors:  M Freund; H D Kleine
Journal:  Infection       Date:  1992       Impact factor: 3.553

6.  Timing of recombinant human granulocyte colony-stimulating factor administration on neutropenia induced by cyclophosphamide in normal mice.

Authors:  M Misaki; Y Ueyama; G Tsukamoto; T Matsumura
Journal:  Br J Cancer       Date:  1998-03       Impact factor: 7.640

7.  Paclitaxel, ifosfamide and cisplatin with granulocyte colony-stimulating factor or recombinant human interleukin 3 and granulocyte colony-stimulating factor in ovarian cancer: a feasibility study.

Authors:  G J Veldhuis; P H Willemse; J H Beijnen; H Boonstra; H Piersma; W T van der Graaf; E G de Vries
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

8.  Effect of alternating combination chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, cisplatin, and etoposide for small cell lung cancer on hematopoietic progenitors in the peripheral blood.

Authors:  E Shimizu; A Yamamoto; Y Takahashi; K Maniwa; S Yoshida; J Mukai; Y Takaue; T Ogura
Journal:  Br J Cancer       Date:  1993-04       Impact factor: 7.640

9.  Granulocyte-colony-stimulating factor enhances the circulating hematopoietic progenitors in lung cancer patients treated with cisplatin-containing regimens.

Authors:  J Mukai; E Shimizu; T Ogura
Journal:  Jpn J Cancer Res       Date:  1992-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.